| [1] |
Fan M,Geng S,Liu Y, et al. Nanocrystal technology as a strategy to improve drug bioavailability and antitumor efficacy for the cancer treatment[J].Curr Pharm Des, 2018, 24(21)：2416-2424.
|
| [2] |
Huang ZG,Lv FM,Wang J, et al. RGD-modified PEGylated paclitaxel nanocrystals with enhanced stability and tumor-targeting capability[J].Int J Pharm,2019,556:217-225.
|
| [3] |
Gao L,Liu G,Ma J, et al. Drug nanocrystals: in vivo performances[J]. J Control Release, 2012, 160(3):418-430.
|
| [4] |
Kalyane D,Raval N,Maheshwari R,et al. Employment of enhanced permeability and retention effect (EPR): nanoparticle-based precision tools for targeting of therapeutic and diagnostic agent in cancer[J].Mater Sci Eng C, 2019,98:1252-1276.
|
| [5] |
Zheng HL,Song YZ,Deng YH.A review for phagocyte system: the executors of nanoparticles clearance[J].J Shenyang Pharm Univ（沈阳药科大学学报）,2019,36(1):91-102.
|
| [6] |
Wilhelm S,Tavares A,Dai Q,et al. Analysis of nanoparticle delivery to tumours[J].Nat Rev Mater, 2016, 1(5):1-12.
|
| [7] |
Ma YQ,Zhang ZZ,Li G,et al.The research progress on nanocrystal technology and its targeted delivery[J].Chin J Hosp Pharm（中国医院药学杂志）,2018,38(9):1014-1017.
|
| [8] |
Mishra P,Nayak B,Dey RK.PEGylation in anti-cancer therapy: an overview[J]. Asian J Pharm Sci, 2016, 11(3):337-348.
|
| [9] |
Sharma S, Singh J, Verma A, et al. Hyaluronic acid anchored paclitaxel nanocrystals improves chemotherapeutic efficacy and inhibits lung metastasis in tumor-bearing rat model[J]. RSC Advances, 2016, 6(77):73083-73095.
|
| [10] |
Yin TJ,Cai H,Liu JY,et al. Biological evaluation of PEG modified nanosuspensions based on human serum albumin for tumor targeted delivery of paclitaxel[J]. Eur J Pharm Sci, 2015, 83:79-87.
|
| [11] |
Zhao J,Liu YY,Wang LL,et al.Functional and modified nanocrystals technology for target drug delivery[J].J Nanosci Nanotechnol,2018,18(8):5207-5221.
|
| [12] |
Zhang WP,Chen YW,Zhang K,et al.Research of folic acid mediated targeted drug delivery system[J].Chin Arch Tradit Chin Med(中华中医药学刊),2017,35(7):1855-1859.
|
| [13] |
Hong JY,Sun ZH,Li YJ,et al. Folate modified annonaceous acetogenins (ACGs) nanosuspensions and improved anti-tumor efficacy[J].Int J Nanomedicine,2017,12:5053-5067.
|
| [14] |
Sun XF,Liu T,Ling Y,et al.Advances in research of hyaluronic acid modified nanomicelles for targeting tumor therapy and drug release behavior[J].J China Pharm Univ(中国药科大学学报）,2019，50（6）：641-647.
|
| [15] |
Wan L, Jiao J, Cui Y, et al. Hyaluronic acid modified mesoporous carbon nanoparticles for targeted drug delivery to CD44-overexpressing cancer cells[J]. Nanotechnology, 2016, 27(13):102-115.
|
| [16] |
Agrawal S,Dwivedi M,Ahmad H, et al. CD44 targeting hyaluronic acid coated lapatinib nanocrystals foster the efficacy against triple-negative breast cancer[J].Nanomedicine, 2018, 14(2):327-337.
|
| [17] |
Gomme PT,Mccann KB, Bertolini J. Transferrin: structure, function and potential therapeutic actions[J]. Drug Discov Today, 2005, 10(4):267-273.
|
| [18] |
Peng J,Zhang YT,Chen J,et al. Structural function and potential clinical value of transferrin[J].Chin J Mod Med(中国现代医学杂志),2017,27(26):56-60.
|
| [19] |
Choi JS,Park JS. Development of docetaxel nanocrystals surface modified with transferrin for tumor targeting[J]. Drug Des Devel Ther, 2016,11:17-26.
|
| [20] |
Sohn JS,Yoon DS,Sohn JY,et al. Development and evaluation of targeting ligands surface modified paclitaxel nanocrystals[J]. Mater Sci Eng C, 2017, 72:228-237.
|
| [21] |
Song ZW,Lin Y,Zhang X, et al. Cyclic RGD peptide-modified liposomal drug delivery system for targeted oral apatinib administration: enhanced cellular uptake and improved therapeutic effects[J].Int J Nanomed, 2017, 12:1941-1958.
|
| [22] |
Sun Y.Advances in research on monoclonal antibodies against tumors[J]. Int J Biologicals(国际生物制品学杂志), 2016, 39(3):128-133.
|
| [23] |
Liang NS. New advances in the research and application of monoclonal antibodies against cancer[J].J China Pharm(中国药房), 2010,21(14):19-22.
|
| [24] |
Noh JK,Naeem M,Cao J,et al. Herceptin-functionalized pure paclitaxel nanocrystals for enhanced delivery to HER2-postive breast cancer cells[J]. Int J Pharm, 2016, 513(1/2):543-553.
|
| [25] |
Danhier F. To exploit the tumor microenvironment: since the EPR effect fails in the clinic, what is the future of nanomedicine[J]. J Control Release, 2016,244:108-121.
|
| [26] |
Mura S,Nicolas J,Couvreur P. Stimuli-responsive nanocarriers for drug delivery[J]. Nat Mater, 2013, 12(11):991-1003.
|
| [27] |
Fuhrmann K,Po?omska A,Aeberli C,et al. Modular design of redox-responsive stabilizers for nanocrystals[J]. ACS Nano, 2013, 7(9):8243-8250.
|
| [28] |
Li TJ,Huang CC,Ruan PW,et al. In vivo anti-cancer efficacy of magnetite nanocrystal - based system using locoregional hyperthermia combined with 5-fluorouracil chemotherapy[J]. Biomaterials, 2013, 34(32):7873-7883.
|
| [29] |
Gao L,Liu GY,Ma JL,et al. Application of drug nanocrystal technologies on oral drug delivery of poorly soluble drugs[J]. Pharm Res, 2013,30(2):307-324.
|
| [30] |
Tuomela A,Saarinen J,Clare J,et al.Production, applications and in vivo fate of drug nanocrystals[J].J Drug Deliv Sci Tec,2016,34:21-31.
|
| [31] |
Mohammad IS,Hu H, Yin L,et al. Drug nanocrystals: fabrication methods and promising therapeutic applications[J].Int J Pharm, 2019,562:187-202.
|
| [32] |
Chen ML,John M,Lee SL,et al. Development considerations for nanocrystal drug products[J].AAPS J,2017,19(3):642-651.
|
| [33] |
Pawar VK, Singh Y, Mehe JG,et al. Engineered nanocrystal technology: in-vivo fate, targeting and applications in drug delivery[J]. J Control Release,2014,183:51-66.
|
| [34] |
Thanuja MY,Anupama C,Ranganath SH. Bioengineered cellular and cell membrane-derived vehicles for actively targeted drug delivery: so near and yet so far[J]. Adv Drug Deliv Rev, 2018,132:57-80.
|
百度学术
下载:
